Ketamine is an anesthetic agent related to PCP (angel dust). Because of this, it has the tendency to produce hallucinations and paranoid delusions. It has been studied in adults with CRPS and, over 12 weeks, there was a reduction in pain that was most notable the 1st week of therapy, but there was no difference between ketamine and placebo at the end of the study. Even with the reduction in pain, there was no improvement in function. In a study of oral ketamine in 12 children with chronic pain it seemed effective in 5, but did not last longer than 12 months and in the one child who had amplified musculoskeletal pain in this study it was not helpful.

Ketamine comas are not approved in the United States, are very controversial, and have not been proven to have any lasting benefit. Ketamine comas have been associated with paralysis, pneumonia, and pulmonary embolus (which can be life threatening).

There is increasing recognition of liver toxicity as well as prolonged mania.

We had one patient who, years later, was still suffering hallucinogenic flashbacks after having ketamine infusions. We saw another patient who did well initially after a ketamine coma in Germany, but after 40 booster ketamine injections she had such severe pain in her feet that she could not even touch them to the floor.  Both of these patients did well in an intense physical and occupational therapy program.

Possible side effects of ketamine include:

  • Death
  • Hallucinations
  • Prolonged Mania
  • Paranoia
  • Psychotic symptoms
  • Liver toxicity
  • Addiction/drug abuse
  • Heart problems (arrhythmia)
  • Breathing difficulties
  • Ridged muscles
  • Extreme pain
  • Nausea and vomiting


  1. Sigtermans MJ, van Hilten JJ, Bauer MC, et al. Ketamine produces effective and long-term pain relief in patients with Complex Regional Pain Syndrome Type 1. Pain 2009;145:304-11.
  2. Patil S, Anitescu M. Efficacy of outpatient ketamine infusions in refractory chronic pain syndromes: a 5-year retrospective analysis. Pain Medicine 2012;13:263-9.
  3. Bredlau AL, McDermott MP, Adams HR, et al. Oral ketamine for children with chronic pain: a pilot phase 1 study. Journal of Pediatrics 2013;163:194-200.e1.
  4. Bell RF. Ketamine for chronic noncancer pain: concerns regarding toxicity. Current Opinion in Supportive & Palliative Care 2012;6:183-7.
  5. Noppers IM, Niesters M, Aarts LP, et al. Drug-induced liver injury following a repeated course of ketamine treatment for chronic pain in CRPS type 1 patients: a report of 3 cases. Pain 2011;152:2173-8.
  6. Ricke AK, Snook RJ, Anand A. Induction of prolonged mania during ketamine therapy for reflex sympathetic dystrophy. Biological Psychiatry 2011;70:e13-4.
  7. Sear JW. Ketamine hepato-toxicity in chronic pain management: another example of unexpected toxicity or a predicted result from previous clinical and pre-clinical data? Pain 2011;152:1946-7.
  8. Henson P, Bruehl S. Complex regional pain syndrome: state of the art update. Current treatment options in cardiovascular medicine 2010;12:156-67.

Comments are closed.